|
|
Line 181: |
Line 181: |
| *There is no reliable evidence that e-cigarette use is associated with ever having had a myocardial infarction among never smokers. | | *There is no reliable evidence that e-cigarette use is associated with ever having had a myocardial infarction among never smokers. |
| *Citation: Critcher, C. R., & Siegel, M. (2021). Re-examining the Association Between E-Cigarette Use and Myocardial Infarction: A Cautionary Tale. American journal of preventive medicine, 61(4), 474–482. https://doi.org/10.1016/j.amepre.2021.05.003 | | *Citation: Critcher, C. R., & Siegel, M. (2021). Re-examining the Association Between E-Cigarette Use and Myocardial Infarction: A Cautionary Tale. American journal of preventive medicine, 61(4), 474–482. https://doi.org/10.1016/j.amepre.2021.05.003 |
|
| |
| ===Biomarkers of Inflammation and Oxidative Stress Among Adult Former Smoker, Current E-Cigarette Users Results from Wave 1 PATH Study===
| |
| Exclusive e-cigarette users have biomarker concentrations that are similar to those of former smokers who do not currently use tobacco, and lower than those of exclusive cigarette smokers.
| |
|
| |
|
| ===2021: Increased Expression of Proatherogenic Proteins in Immune Cell Subtypes in Tobacco Cigarette Smokers But Not in Electronic Cigarette Vapers=== | | ===2021: Increased Expression of Proatherogenic Proteins in Immune Cell Subtypes in Tobacco Cigarette Smokers But Not in Electronic Cigarette Vapers=== |